Tempest Therapeutics (Tempest Therapeutics) Cash-to-Debt : 1.90 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tempest Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.90.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tempest Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Tempest Therapeutics's Cash-to-Debt or its related term are showing as below:

TPST' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.41 Med: 2.35 Max: 7.72
Current: 1.9

During the past 4 years, Tempest Therapeutics's highest Cash to Debt Ratio was 7.72. The lowest was 1.41. And the median was 2.35.

TPST's Cash-to-Debt is ranked worse than
68.77% of 1540 companies
in the Biotechnology industry
Industry Median: 6.575 vs TPST: 1.90

Tempest Therapeutics Cash-to-Debt Historical Data

The historical data trend for Tempest Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tempest Therapeutics Cash-to-Debt Chart

Tempest Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

7.72

2.80

1.41

1.90

Tempest Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial										1.41	1.06	0.82	0.53	1.90

Competitive Comparison of Tempest Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Tempest Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's Cash-to-Debt falls into.

Tempest Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tempest Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.23	/	(5.237	+	15.424)
	=	1.90

Tempest Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.23	/	(5.237	+	15.424)
	=	1.90

Tempest Therapeutics (NAS:TPST) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tempest Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics (Tempest Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

3OS:Germany 3OS:Germany

Address

2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005

Website

https://www.tempesttx.com

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Executives

Justin Trojanowski	officer: Corporate Controller	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas	officer: VP of Strategy and Finance	7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky	director, officer: President	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Samuel Whiting	officer: Chief Medical Officer	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Rock Springs Capital Llc	10 percent owner	650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202